Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06783881
PHASE1

Single-ascending Dose Study of Kylo-12 in Healthy Subjects

Sponsor: Kylonova (Xiamen) Biopharma co., LTD.

View on ClinicalTrials.gov

Summary

This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers. Kylo-12 will be evaluated in approximately 50 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.

Official title: A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Kylo-12 in Healthy Subjects

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2025-03-12

Completion Date

2026-08-30

Last Updated

2026-03-16

Healthy Volunteers

Yes

Interventions

DRUG

Kylo-12

Administered SC.

DRUG

Placebo

Administered SC.

Locations (1)

Chengdu Xinhua Hospital

Chengdu, Sichuan, China